<DOC>
	<DOCNO>NCT00418496</DOCNO>
	<brief_summary>The primary objective study determine toxicity Maximum Tolerated Dose ( MTD ) combination high dose aldesleukin sorafenib previously untreated patient metastatic unresectable clear cell renal carcinoma ( RCC ) metastatic melanoma .</brief_summary>
	<brief_title>Interleukin-2 With Sorafenib ( BAY 43-9006 ) Unresectable Metastatic Clear Cell Renal Carcinoma ( RCC ) Metastatic Melanoma</brief_title>
	<detailed_description>Rationale : Previous research indicate high dose aldesleukin produce tumor regression upregulation patient ' immune system . Research suggest sorafenib directly target tumor inhibit angiogenic activity possibly cytotoxicity . Angiogenic refers formation new blood vessel support tumor growth . Cytotoxicity measurement chemical 's ability damage kill cancer cell . Researchers hypothesize complementary way aldesleukin sorafenib work , non-overlapping toxicity profile , may create reasonable combination treatment metastatic renal cell carcinoma metastatic melanoma . The current Phase I study evaluate toxicity patient assess various dose level sorafenib combination aldesleukin . Purpose : The primary objective determine maximum tolerate dose characterize toxicity high dose aldesleukin sorafenib patient unresectable metastatic clear cell renal carcinoma metastatic melanoma . Secondary objective include determine progression free survival patient , evaluate preliminary manner response rate , assess measurement study participant . Treatment : Study participant give bolus high dose aldesleukin sorafenib . Aldesleukin provide intravenous infusion day 1 5 . Each 5 day treatment consider cycle . The second cycle aldesleukin start day 15 . Two cycle consider 1 course . All study participant give dose level aldesleukin . No dose reduction permit . Sorafenib administer day 29 . Since study ass maximum tolerate dose sorafenib , study participant receive different amount drug compare others depend upon individual enrolls study . Each group 3 6 study participant receive high dose sorafenib maximum tolerate dose establish . Imagining study perform determine response treatment week 12 . If patient stable respond disease , second course administer schedule . Patients without disease response give one additional course aldesleukin past maximal response . When decide aldesleukin provide patient , sorafenib Food Drug Administration approve dose may continue lack clinical benefit intolerable side effect develop . Several test exams give throughout study closely monitor patient .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients must histologically cytologically confirm evidence metastatic/ unresectable clear cell renal carcinoma . Patients must metastatic melanoma brain metastasis . Patients must measurable disease . No prior systemic treatment ( One prior systemic treatment allow metastatic melanoma patient . Excluded prior therapy include prior high dose aldesleukin , sorafenib DTIC/TMZ . ) Age â‰¥ 18 year old Patients undergo undergone surgery S week . Patients pregnant ( possible side effect fetus ) Effective contraception discuss patient . Patients uveal melanoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Unresectable</keyword>
	<keyword>Metastatic</keyword>
</DOC>